p-Tau immunotherapy reduces soluble and insoluble tau in aged 3xTg-AD mice

Alzheimer’s disease (AD) is a proteinopathy characterized by the accumulation of β-amyloid (Aβ) and tau. To date, clinical trials indicate that Aβ immunotherapy does not improve cognition. Consequently, it is critical to modulate other aspects of AD pathology. As such, tau represents an excellent ta...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Neurosci Lett
Asıl Yazarlar: Walls, Ken C., Ager, Rahasson R., Vasilevko, Vitaly, Cheng, Dave, Medeiros, Rodrigo, LaFerla, Frank M.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2014
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4437620/
https://ncbi.nlm.nih.gov/pubmed/24887583
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.neulet.2014.05.047
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller